Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical market, timing is everything. Patent cliffs don’t just determine when a drug becomes cheaper; they determine when formularies change, when procuremen…

Generic launches don’t “happen.” They arrive—on a schedule shaped by patents, exclusivities, and regulatory timing.
Most teams still forecast generic entry like it’s a calendar exercise: look up the Orange Book, estimate a date, move on. That approac…

Most people treat the FDA Orange Book like a static database. That’s why they miss the real signal.
If you’re a business development leader, investor, or sourcing professional in pharma, you already know the Orange Book is where the “official” patent s…

Biotech investors love “pipeline quality.” But portfolio decisions often get made with a foggy metric: gut feel.
Here’s the uncomfortable truth: when you’re ranking R&D programs, you’re really ranking future cashflows under uncertainty. And the too…

Biopharma’s “patent cliff” isn’t just a pricing story—it’s a talent story.
Most people talk about the cliff in terms of revenue: when exclusivity ends, generic and biosimilar competition arrives, margins compress, and pipelines get scrutinized. But t…

Stop Overstocking Branded Drugs: Patent Intelligence Is the New Risk Control for Wholesalers
Branded drug inventory risk isn’t just a balance-sheet problem—it’s a timing problem.
When wholesalers overstock branded products, they’re often betting on a f…

Big Pharma doesn’t just “feel” a patent cliff—it hires around it.
That may sound counterintuitive. We’re trained to think of patent expirations as a sales-and-margin story: generic entry hits, revenue softens, and leadership responds with cost cuts or …

Biosimilar sourcing isn’t a procurement problem—it’s a patent strategy problem.
If you’re planning a switch from an originator biologic to a biosimilar, the hardest part usually isn’t identifying candidates. It’s timing. It’s sequencing. It’s making su…

Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines
There’s a quiet shift happening across healthcare: medicines that were once “good enough” are being reintroduced—often with new indications, new formulations, or new d…

Pharma recruiters don’t just “find” scientists. They trace them.
In a world where résumés blur together and LinkedIn keywords are easy to game, the most reliable signal is often hiding in plain sight: patent citations.
Think of patent citations as the …